Alvogen Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH244844D
- Pages: 40
- November 2018
- Total Views:1148
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Alvogen Inc (Alvogen) is a pharmaceutical company that develops, manufactures and markets generic pharmaceuticals, brand and over the counter (OTC) products. The company offers generic medications in the therapeutic areas of oncology, cardiology, respiratory, neurology and gastroenterology. It also provides services such as product development, contract manufacturing and research services. Alvogen's OTC categories include food supplements, OTC medicines, cosmetics and medical devices. It offers products in various dosage forms of solid oral dosage, modified release tablets, soft gelatin capsules, creams, ointments, transdermals and injectables. The company operates through its manufacturing and development facilities located in the US, Taiwan, South Korea and Romania. Alvogen is headquartered in Pine Brook, New Jersey, the US.
Alvogen Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alvogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alvogen Inc, Medical Devices Deals, 2012 to YTD 2018 10
Alvogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Alvogen Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Lotus Pharma Acquires Osteoporosis from Novartis 13
Alvogen Acquires Five Hormonal Products from Bayer Pharma 14
Alvogen to Acquire Four Pharma Products from Pfizer 15
Private Equity 16
CVC Capital, Temasek and Vatera Healthcare Partners Acquire Majority Stake in Alvogen 16
Pamplona Capital Management Acquires Majority Stake In Alvogen 18
Partnerships 19
Alvogen Enters into Distribution Agreement with Theramex 19
Lotus Pharma, Tzu Chi Hospital and EF Biotech to Enter into Agreement 20
Alvogen Enters into Marketing Agreement with AstraZeneca 21
Probi Enters Into Distribution Agreement With Alvogen 22
Licensing Agreements 23
Alvogen Enters into Licensing Agreement with Prestige BioPharma 23
Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 24
Luye Pharma Enters into Licensing Agreement with Lotus Pharma 25
Asset Transactions 26
Lotus Pharma Plans to Sell Product Rights 26
Acquisition 27
CVC Capital, Temasek and Vatera Healthcare May Sell Alvogen for up to USD4 Billion 27
Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 28
Alvogen Acquires County Line Pharma 29
Alvogen Acquires Dream Pharma for USD184 Million 30
Alvogen To Acquire 67% Stake In Lotus Pharma For USD 205 Million 31
Alvogen Completes Acquisition Of LaborMed Pharma, Maker Of Generic Drugs 32
Alvogen Completes Acquisition Of 67% Stake In KunWha Pharma For USD 68 Million 33
Alvogen Inc-Key Competitors 34
Alvogen Inc-Key Employees 35
Alvogen Inc-Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 38
Corporate Communications 38
Jan 16, 2018: Lotus Enters Management Team Integration With Alvogen-Petar Vazharov Steps Up As Lotus General Manager 38
Legal and Regulatory 39
Aug 10, 2018: Drugmaker sues, asks court to block use of its product in Nevada execution on Wednesday 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List Of Figure
List of Figures
Alvogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alvogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alvogen Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Alvogen Inc, Pharmaceuticals & Healthcare, Key Facts 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alvogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alvogen Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Alvogen Inc, Medical Devices Deals, 2012 to YTD 2018 10
Alvogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lotus Pharma Acquires Osteoporosis from Novartis 13
Alvogen Acquires Five Hormonal Products from Bayer Pharma 14
Alvogen to Acquire Four Pharma Products from Pfizer 15
CVC Capital, Temasek and Vatera Healthcare Partners Acquire Majority Stake in Alvogen 16
Pamplona Capital Management Acquires Majority Stake In Alvogen 18
Alvogen Enters into Distribution Agreement with Theramex 19
Lotus Pharma, Tzu Chi Hospital and EF Biotech to Enter into Agreement 20
Alvogen Enters into Marketing Agreement with AstraZeneca 21
Probi Enters Into Distribution Agreement With Alvogen 22
Alvogen Enters into Licensing Agreement with Prestige BioPharma 23
Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 24
Luye Pharma Enters into Licensing Agreement with Lotus Pharma 25
Lotus Pharma Plans to Sell Product Rights 26
CVC Capital, Temasek and Vatera Healthcare May Sell Alvogen for up to USD4 Billion 27
Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 28
Alvogen Acquires County Line Pharma 29
Alvogen Acquires Dream Pharma for USD184 Million 30
Alvogen To Acquire 67% Stake In Lotus Pharma For USD 205 Million 31
Alvogen Completes Acquisition Of LaborMed Pharma, Maker Of Generic Drugs 32
Alvogen Completes Acquisition Of 67% Stake In KunWha Pharma For USD 68 Million 33
Alvogen Inc, Key Competitors 34
Alvogen Inc, Key Employees 35
Alvogen Inc, Subsidiaries 36
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Alvogen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Alvogen Inc (Alvogen) is a pharmaceutical company that develops, manufactures and markets generic pharmaceuticals, brand and over the counter (OTC) products. The company offers generic medications in the therapeutic areas of oncology, cardiology, respiratory, neurology and gastroenterology. It also provides services such as product development, contract manufacturing and research services. Alvogen's OTC categories include food supplements, OTC medicines, cosmetics and medical devices. It offers products in various dosage forms of solid oral dosage, modified release tablets, soft gelatin capsules, creams, ointments, transdermals and injectables. The company operates through its manufacturing and development facilities located in the US, Taiwan, South Korea and Romania. Alvogen is headquartered in Pine Brook, New Jersey, the US.
Alvogen Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alvogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alvogen Inc, Medical Devices Deals, 2012 to YTD 2018 10
Alvogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Alvogen Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Lotus Pharma Acquires Osteoporosis from Novartis 13
Alvogen Acquires Five Hormonal Products from Bayer Pharma 14
Alvogen to Acquire Four Pharma Products from Pfizer 15
Private Equity 16
CVC Capital, Temasek and Vatera Healthcare Partners Acquire Majority Stake in Alvogen 16
Pamplona Capital Management Acquires Majority Stake In Alvogen 18
Partnerships 19
Alvogen Enters into Distribution Agreement with Theramex 19
Lotus Pharma, Tzu Chi Hospital and EF Biotech to Enter into Agreement 20
Alvogen Enters into Marketing Agreement with AstraZeneca 21
Probi Enters Into Distribution Agreement With Alvogen 22
Licensing Agreements 23
Alvogen Enters into Licensing Agreement with Prestige BioPharma 23
Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 24
Luye Pharma Enters into Licensing Agreement with Lotus Pharma 25
Asset Transactions 26
Lotus Pharma Plans to Sell Product Rights 26
Acquisition 27
CVC Capital, Temasek and Vatera Healthcare May Sell Alvogen for up to USD4 Billion 27
Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 28
Alvogen Acquires County Line Pharma 29
Alvogen Acquires Dream Pharma for USD184 Million 30
Alvogen To Acquire 67% Stake In Lotus Pharma For USD 205 Million 31
Alvogen Completes Acquisition Of LaborMed Pharma, Maker Of Generic Drugs 32
Alvogen Completes Acquisition Of 67% Stake In KunWha Pharma For USD 68 Million 33
Alvogen Inc-Key Competitors 34
Alvogen Inc-Key Employees 35
Alvogen Inc-Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 38
Corporate Communications 38
Jan 16, 2018: Lotus Enters Management Team Integration With Alvogen-Petar Vazharov Steps Up As Lotus General Manager 38
Legal and Regulatory 39
Aug 10, 2018: Drugmaker sues, asks court to block use of its product in Nevada execution on Wednesday 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List Of Figure
List of Figures
Alvogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alvogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alvogen Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Alvogen Inc, Pharmaceuticals & Healthcare, Key Facts 2
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alvogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alvogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alvogen Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Alvogen Inc, Medical Devices Deals, 2012 to YTD 2018 10
Alvogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lotus Pharma Acquires Osteoporosis from Novartis 13
Alvogen Acquires Five Hormonal Products from Bayer Pharma 14
Alvogen to Acquire Four Pharma Products from Pfizer 15
CVC Capital, Temasek and Vatera Healthcare Partners Acquire Majority Stake in Alvogen 16
Pamplona Capital Management Acquires Majority Stake In Alvogen 18
Alvogen Enters into Distribution Agreement with Theramex 19
Lotus Pharma, Tzu Chi Hospital and EF Biotech to Enter into Agreement 20
Alvogen Enters into Marketing Agreement with AstraZeneca 21
Probi Enters Into Distribution Agreement With Alvogen 22
Alvogen Enters into Licensing Agreement with Prestige BioPharma 23
Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 24
Luye Pharma Enters into Licensing Agreement with Lotus Pharma 25
Lotus Pharma Plans to Sell Product Rights 26
CVC Capital, Temasek and Vatera Healthcare May Sell Alvogen for up to USD4 Billion 27
Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 28
Alvogen Acquires County Line Pharma 29
Alvogen Acquires Dream Pharma for USD184 Million 30
Alvogen To Acquire 67% Stake In Lotus Pharma For USD 205 Million 31
Alvogen Completes Acquisition Of LaborMed Pharma, Maker Of Generic Drugs 32
Alvogen Completes Acquisition Of 67% Stake In KunWha Pharma For USD 68 Million 33
Alvogen Inc, Key Competitors 34
Alvogen Inc, Key Employees 35
Alvogen Inc, Subsidiaries 36
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Alvogen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020